肾癌分期何时应行术前胸部计算机断层扫描
本研究基于前瞻性机构数据库中1946例接受手术治疗的肾细胞癌(RCC)患者,分析术前分期胸部CT阳性(肺转移)的预测因素。术前胸部CT阳性率为6%(n=119);多因素logistic回归显示≥cT1b、cN1、全身症状及血红蛋白/血小板比值与胸部CT阳性风险升高相关(均P<0.001),一致性指数为0.88。作者据此提出对≥cT1b、cN1、全身症状或贫血伴血小板增多者推荐胸部CT,对cT1a、cN0且无上述表现者可省略胸部CT。
要点
- 术前胸部CT阳性率为6%(n=119),≥cT1b、cN1、全身症状及血红蛋白/血小板比值与阳性风险升高相关(均P<0.001)。
- 模型一致性指数为0.88;若对阳性风险>1%者行胸部CT,37%的人群可避免阴性胸部CT,仅0.2%的人群会漏诊阳性胸部CT。
- 作者建议对≥cT1b、cN1、全身症状或贫血伴血小板增多者行胸部CT,对cT1a、cN0且无全身症状、贫血和血小板增多者可省略胸部CT。
核心结论
- 作者认为该策略能以最佳准确性估计RCC分期胸部CT阳性风险,结果具有统计学和临床意义,支持对≥cT1b、cN1、全身症状或贫血伴血小板增多者推荐胸部CT,对cT1a、cN0且无全身症状、贫血和血小板增多者可省略胸部CT。
研究设计与样本
- 研究纳入前瞻性机构数据库中1946例接受手术治疗的RCC患者,结局为分期胸部CT发现肺转移,并建立多因素logistic回归模型预测胸部CT阳性。
主要发现
- 胸部CT阳性率为6%(n=119);多因素logistic回归中≥cT1b、cN1、全身症状和Hb/PLT比值均与胸部CT阳性风险升高相关(均P<0.001)。
- 经2000次bootstrap验证后一致性指数为0.88;决策曲线分析中该策略的净获益优于全部选择和全部不选择策略。
- 若在阳性结果风险>1%时行胸部CT,37%的人群可避免阴性胸部CT,仅0.2%的人群会漏诊阳性胸部CT。
关键数值与推荐
- 预测因素包括术前临床肿瘤(cT)分期、临床淋巴结(cN)分期、全身症状及血小板计数(PLT)/血红蛋白(Hb)比值。
- 胸部CT阳性率为6%(n=119);≥cT1b、cN1、全身症状和Hb/PLT比值与阳性风险升高相关(均P<0.001);一致性指数为0.88。
- 若胸部CT阳性风险>1%时行胸部CT,37%的人群可避免阴性胸部CT,0.2%的人群会漏诊阳性胸部CT。
临床怎么用
- 作者建议对≥cT1b、cN1、全身症状或贫血伴血小板增多者行胸部CT,对cT1a、cN0且无全身症状、贫血和血小板增多者可省略胸部CT。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To provide objective criteria for preoperative staging chest computed tomography (CT) in patients diagnosed with renal cell carcinoma (RCC) because, in the absence of established indications, the decision for preoperative chest CT remains subjective. PATIENTS AND METHODS: A total of 1 946 patients undergoing surgical treatment of RCC, whose data were collected in a prospective institutional database, were assessed. The outcome of the study was presence of pulmonary metastases at staging chest CT. A multivariable logistic regression model predicting positive chest CT was fitted. Predictors consisted of preoperative clinical tumour (cT) and nodal (cN) stage, presence of systemic symptoms and platelet count (PLT)/haemoglobin (Hb) ratio. RESULTS: The rate of positive chest CT was 6% (n = 119). At multivariable logistic regression, ≥cT1b, cN1, systemic symptoms and Hb/PLT ratio were all associated with higher risk of positive chest CT (all P < 0.001). After 2000-sample bootstrap validation, the concordance index was found to be 0.88. At decision-curve analysis, the net benefit of the proposed strategy was superior to the select-all and select-none strategies. Accordingly, if chest CT had been performed when the risk of a positive result was >1%, a negative chest CT would have been spared in 37% of the population and a positive chest CT would have been missed in 0.2% of the population only. CONCLUSIONS: The proposed strategy estimates the risk of positive chest CT at RCC staging with optimum accuracy and the results were statistically and clinically relevant. The findings of the present study support a recommendation for chest CT in patients with ≥cT1b, cN1, systemic symptoms or anaemia and thrombocythemia. Conversely, in patients with cT1a, cN0 without systemic symptoms, anaemia and thrombocythemia, chest CT could be omitted.
引用
- Larcher A, Dell'Oglio P, Fossati N, et al. When to perform preoperative chest computed tomography for renal cancer staging. BJU Int. 2016. PMID: 27684653. doi:10.1111/bju.13670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。